Nakajima K, Yoshita M, Matsuo S, Taki J, Kinuya S
Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Japan.
Q J Nucl Med Mol Imaging. 2008 Dec;52(4):378-87.
Iodine-123-labeled metaiodobenzylguanidine (MIBG) has a history of over 20 years as a marker of myocardial sympathetic activity in Japan and has been used for various cardiac diseases. Aside from conventional utilities in patients with cardiac diseases, including ischemic heart diseases, cardiomyopathy, heart failure and diabetes, neurological disorders have recently been drawing special attention. The [(123)I]MIBG study showed markedly decreased myocardial uptake in Parkinson's disease, dementia with Lewy bodies and pure autonomic failure, which is a common feature of Lewy-body diseases. The MIBG study can be used for differentiating patients with extrapyramidal signs and dementia. The unique application of MIBG in movement disorders and related neurological diseases is one of its most common uses in Japan, and further studies are expected worldwide.
在日本，碘-123标记的间碘苄胍（MIBG）作为心肌交感神经活动标志物已有20多年历史，并已用于各种心脏疾病。除了在包括缺血性心脏病、心肌病、心力衰竭和糖尿病等心脏病患者中的传统应用外，神经疾病最近也受到了特别关注。[（123）I]MIBG研究显示，帕金森病、路易体痴呆和纯自主神经功能衰竭患者的心肌摄取明显降低，这是路易体病的一个共同特征。MIBG研究可用于鉴别有锥体外系体征和痴呆的患者。MIBG在运动障碍及相关神经疾病中的独特应用是其在日本最常见的用途之一，预计全球将开展进一步研究。
